Insider · CIK 0001608536
Scott M Coiante
Files at LXRX (LEXICON PHARMACEUTICALS, INC.). First filing -, latest -.
In brief
Scott M Coiante files SEC Form 4 as CFO at LXRX (LEXICON PHARMACEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Scott M Coiante has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +160,237 | - | - | 160,237 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | FTax withholding Common Stock | -54,881 | $1.47 | $81k | 105,356 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -160,237 | - | - | 320,473 | Mar 3, 2026 |
| Feb 12, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +272,680 | $0.00 | $0 | 272,680 | Feb 17, 2026 |
| Feb 12, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +409,020 | $0.00 | $0 | 409,020 | Feb 17, 2026 |
| Feb 13, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +721,070 | $0.00 | $0 | 721,070 | Feb 18, 2025 |
| Feb 13, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +480,710 | $0.00 | $0 | 480,710 | Feb 18, 2025 |
| Jan 2, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +230,000 | $0.00 | $0 | 230,000 | Jan 2, 2025 |
Questions about Scott M Coiante
Answered from the filings on this page, as of the latest one.
Is Scott M Coiante buying or selling?
Scott M Coiante has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Scott M Coiante's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Scott M Coiante has 0.
Where does Scott M Coiante file Form 4?
Scott M Coiante has filed Form 4 at LXRX (LEXICON PHARMACEUTICALS, INC.) as SVP, Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.